Aranscia
Aranscia is a Houston-based precision medicine platform operating four subsidiaries (2bPrecise, AccessDx Laboratory, Spesana, YouScript) that deliver EMR-integrated clinical workflow software, pharmacogenomics decision support, and diagnostic laboratory services to health systems, oncology centers, ACOs, and patients.
- Company typePrivate
- Founded-
- HeadquartersHouston, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Aranscia does
Aranscia is a privately-held precision medicine company headquartered in Houston, Texas, that operates a portfolio of four wholly-owned subsidiaries — 2bPrecise (EMR-integrated clinical workflow software), AccessDx Laboratory (a CLIA-certified, CAP-accredited, NYSDOH-approved diagnostic lab), Spesana (clinical workflow and oncology decision support, acquired May 2025), and YouScript (pharmacogenomics decision support, acquired November 2023 from Invitae). The company delivers pharmacogenomics, infectious disease management, precision oncology, and genetic screening programs to health systems, hospitals, oncology centers, ACOs, municipalities, and individual patients, with software that is deliberately EMR-agnostic and lab-agnostic so it can be deployed without replacing existing systems.
The underlying technology stack combines 2bPrecise's lab-agnostic point-of-care software, Spesana's patient navigation and prior-authorization utilities, and YouScript's medication risk algorithms, all anchored by AccessDx Laboratory's molecular diagnostic testing infrastructure. The portfolio is integrated through a shared technology and services architecture that allows clinical organizations to launch turnkey precision medicine programs and gives diagnostic developers (e.g., InterVenn, Neurogen) a distribution and workflow layer for commercializing new tests. Two decades of peer-reviewed YouScript pharmacogenomics research underpins the evidence base, with reported outcomes including a 71% reduction in ED visits and 39% reduction in hospital admissions in a University of Utah study.
Aranscia's business model rests on three revenue streams: software licensing and SaaS subscriptions for its clinical workflow products, fee-for-service laboratory testing through AccessDx, and managed-services-style partnerships with diagnostic developers that bundle software and lab infrastructure. The company has executed two acquisitions in 18 months (YouScript, Spesana) and three major strategic partnerships (Signature RX for GLP-1, Neurogen Biomarking for Alzheimer's, InterVenn Biosciences for ovarian cancer), signaling an active rollup strategy supported by undisclosed capital. Customers span thousands of discrete client groups across primary healthcare and government segments, with GTM executed through enterprise field sales and a direct-to-consumer testing channel via AccessDx.
Aranscia firmographics
Firmographics- Name
- Aranscia
- Legal name
- Aranscia
- Website
- https://aranscia.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Aranscia is a Houston-based precision medicine platform operating four subsidiaries (2bPrecise, AccessDx Laboratory, Spesana, YouScript) that deliver EMR-integrated clinical workflow software, pharmacogenomics decision support, and diagnostic laboratory services to health systems, oncology centers, ACOs, and patients.
- Ownership category
- akta.pro rank
Aranscia industry classification
Industry- Product category
- Precision Medicine Software and Diagnostic Services
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Software Publishers (513210)
- SIC
- Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history) (HLALAIAD), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Pharmacy Interoperability, Standards & Integration (FHIR/NCPDP) (HLACAKAO)
Keywords
Where Aranscia is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aranscia business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Software Licensing and SaaS: Aranscia provides clinical workflow software solutions (2bPrecise, Spesana, YouScript) to healthcare organizations. Revenue derived from software licensing, subscriptions, and clinical decision support tools integrated into EMR systems.
- Laboratory Testing Services: AccessDx Laboratory provides diagnostic testing services including pharmacogenomic testing, cancer genomic testing, respiratory pathogen panels, and other clinical laboratory services. Revenue from test processing and laboratory services.
- Partnership and Collaboration Services: Multi-year partnerships with companies like InterVenn Biosciences and Neurogen Biomarking provide technical, operational, and analytical support resources through AccessDx Laboratory and software solutions.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels10 records
Aranscia product offering
Product offeringCore offering
Aranscia provides precision medicine software and diagnostic services to clinical organizations through four portfolio brands: 2bPrecise (EMR-agnostic, lab-agnostic clinical workflow software for precision care), AccessDx Laboratory (CLIA-certified, CAP-accredited diagnostic testing services in pharmacogenomics and personalized diagnostics), Spesana (patient navigation, prior authorization, clinical trial collaboration, and oncology decision support software), and YouScript (real-time pharmacogenomics decision support at the point of care). The integrated portfolio enables health systems, hospitals, ACOs, and oncology centers to launch turnkey pharmacogenomics, infectious disease, precision oncology, and genetic screening programs.
Product overview
Aranscia operates as a platform-plus-modules architecture offering a portfolio of integrated diagnostic software, services, and testing innovations. The core portfolio includes 2bPrecise (EMR-integrated software platform for precision care), AccessDx Laboratory (CLIA/CAP-accredited diagnostic testing services), Spesana (acquired clinical workflow and patient navigation solutions), and YouScript (acquired pharmacogenomics decision support). These products work together to enable clinical organizations to utilize precision diagnostics for programs in pharmacogenomics, infectious disease management, precision oncology, and genetic screening, unified by a shared technology and services architecture focused on simplicity and scalability.
Differentiator
Problem solved
Functional benefit
Brands
- 2bPrecise: Award-winning platform for lab-agnostic, EMR-integrated solutions that deliver precision care
- AccessDx Laboratory
- Spesana
- YouScript
Products and services
- 2bPrecise Lab-agnostic, EMR-integrated software platform for precision care workflows including pharmacogenomics, population health insights, and precision oncology. Delivers diagnostic and genomic insights at the point of care within any EMR for health systems, hospitals, ACOs, multi-provider organizations, and oncology centers.
- AccessDx Laboratory CLIA-certified, CAP-accredited, NYSDOH-approved molecular diagnostic laboratory offering pharmacogenomic testing, cancer genomic testing, respiratory pathogen panels, infectious disease diagnostics, and personalized diagnostic services for health systems, ACOs, and direct consumers.
- Spesana Software solutions that increase the velocity of patient access to the right care through patient navigation, prior authorization, clinical trial collaboration, and oncology diagnostic workflow utilities. Used across over 140 clinical sites by oncology centers, health systems, and ACOs.
- YouScript Real-time pharmacogenomic decision support platform that synthesizes evidence impacting drug response to support doctors and pharmacists in faster, more proactive prescribing decisions at the point of care. Validated in peer-reviewed research showing 71% reduction in ED visits and 39% reduction in hospital admissions.
Quantifiable outcome
- 71% reduction in hospital emergency department visits
- +4 more outcomes
Companies that use Aranscia
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Aranscia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aranscia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major.
- InterVenn BiosciencesmajorMulti-year partnership where Aranscia provides software solutions (Spesana, 2bPrecise) and laboratory resources (AccessDx Laboratory) to help InterVenn accelerate commercialization of its GlycoKnow Ovarian cancer diagnostic test. Aranscia's EMR-agnostic clinical workflow utilities facilitate delivery of diagnostic results within women's health, oncology, and health system care settings.
- Neurogen BiomarkingmajorPartnership where AccessDx Laboratory provides technical, operational, and analytical support for Neurogen's blood-based biomarker test measuring phosphorylated tau (p-tau) 217 for Alzheimer's disease. Additionally, 2bPrecise provides HIPAA-compliant EMR-agnostic clinical workflow utilities to integrate diagnostic results across the Neurogen ecosystem.
- Signature RXmajorMulti-phase partnership to develop novel biomarkers and a personalized medication management solution for GLP-1 medications. AccessDx Laboratory dedicates resources to assessment and development of new companion diagnostics for GLP-1 medications. Signature RX also offers the YouScript Personalized Medication Management Program to clinical clients.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Aranscia competitors and assessment
Company assessmentDirect peers
- OneOme: OneOme is a pharmacogenomic testing and clinical decision support company that pairs PGx results with prescribing tools, very similar to Aranscia's YouScript + AccessDx + 2bPrecise stack targeting health systems and providers.
- Genomind: Genomind offers PGx testing (e.g., Mindful DNA) integrated into clinical workflow for medication selection, comparable to YouScript's real-time pharmacogenomic decision support for prescribing.
- Tempus Labs: Tempus combines molecular diagnostics (oncology-focused sequencing) with an EMR-integrated clinical workflow platform, directly comparable to Aranscia's AccessDx testing paired with 2bPrecise/Spesana precision-oncology workflows.
- Caris Life Sciences: Caris offers molecular profiling and companion diagnostics in oncology with associated clinical decision and trial-matching workflows, overlapping with Aranscia's precision-oncology positioning (Spesana, AccessDx).
- Flatiron Health: Flatiron (acquired by Roche) sells oncology-specific EHR and real-world evidence/clinical decision infrastructure, comparable to Spesana's oncology workflow and patient navigation utilities.
- NantHealth: NantHealth provides oncology clinical decision support and care coordination tools, with overlap to Spesana and 2bPrecise's precision-oncology EMR-integrated workflows.
Broad incumbents
- Myriad Genetics: Myriad is an established molecular diagnostics company offering hereditary cancer, pharmacogenomic, and tumor profiling tests, broadly comparable to AccessDx's PGx and cancer genomic testing services.
- Exact Sciences: Exact Sciences (with Genomic Health) operates a large molecular diagnostics franchise in oncology (Cologuard, Oncotype DX), serving as a broad incumbent comparable to AccessDx's diagnostic lab capabilities.
- Quest Diagnostics: Quest Diagnostics runs a national CLIA-certified clinical lab network that has expanded into PGx and specialty molecular testing, broadly comparable to AccessDx's CLIA-certified/CAP-accredited lab services.
Emerging players
- Stanson Health: Stanson Health delivers EMR-integrated clinical decision support and analytics; its point-of-care CDS focus overlaps with 2bPrecise and YouScript's EMR-agnostic decision support positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights6 records
Customer concentration
Aranscia social profiles
Digital presenceAranscia compliance and trust
Trust signalCompliance4 records
Aranscia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aranscia leadership team
Management profileNumber of profiles
Profiles9 records
Aranscia subsidiaries and ownership
Company hierarchySubsidiaries4 records
Aranscia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aranscia M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aranscia
What does Aranscia do?
Aranscia provides precision medicine software and diagnostic services to clinical organizations through four portfolio brands: 2bPrecise (EMR-agnostic, lab-agnostic clinical workflow software for precision care), AccessDx Laboratory (CLIA-certified, CAP-accredited diagnostic testing services in pharmacogenomics and personalized diagnostics), Spesana (patient navigation, prior authorization, clinical trial collaboration, and oncology decision support software), and YouScript (real-time pharmacogenomics decision support at the point of care). The integrated portfolio enables health systems, hospitals, ACOs, and oncology centers to launch turnkey pharmacogenomics, infectious disease, precision oncology, and genetic screening programs.
Is Aranscia a public or private company?
Aranscia is a private company. It is classified as unknown and is currently operating.
When was Aranscia founded?
Aranscia was founded in -1. It employs 101 to 250 people.
Where is Aranscia based?
Aranscia is headquartered in Houston, United States, in the North America region.
How does Aranscia make money?
Three revenue lines are on record. Diagnostic Software Licensing and SaaS are the primary driver. The others are laboratory Testing Services and partnership and Collaboration Services.
Who are Aranscia's main competitors?
Direct peers on record are OneOme, Genomind, Tempus Labs, Caris Life Sciences, Flatiron Health and NantHealth. Broad incumbents are Myriad Genetics, Exact Sciences and Quest Diagnostics. Stanson Health is listed as an emerging player.
Does Aranscia have an API?
No public API is recorded for Aranscia.
What industry is Aranscia in?
Aranscia's product category is Precision Medicine Software and Diagnostic Services. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLALAIAD, ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history). Its NAICS code is 6215 and its SIC code is 8071.